Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study

Sara A. Hurvitz, Miguel Martin, Kyung Hae Jung, Chiun Sheng Huang, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean François Boileau, Peter A. Fasching, Karen Afenjar, Gonzalo Spera, Vanesa Lopez-Valverde, Chunyan Song, Peter Trask, Thomas Boulet, Joseph A. Sparano, W. Fraser Symmans, Alastair M. ThompsonDennis Slamon

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Fingerprint

Dive into the research topics of 'Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study'. Together they form a unique fingerprint.

Medicine & Life Sciences